Local dexmedetomidine in awake fiberoptic intubation

Studying the effect of Dexmedetomidine as local anesthetic adjuvant on sedation and hemodynami status of patients during fiberoptic nasotracheal intubation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015101224493N1

Enrollment

Registered

2016-01-25

Start date

2015-08-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

the quality of awake fiberoptic intubation. -

Interventions

Intervention 1: Control group:airway nerve blocks by lidocaine (5 milligram per kilogram of body weight) and infusion of 20 cc normal saline over 10 minutes before the blocks. Intervention 2: DEX L

Treatment - Drugs

Control group:airway nerve blocks by lidocaine (5 milligram per kilogram of body weight) and infusion of 20 cc normal saline over 10 minutes before the blocks

DEX LOCAL group: infusion of 20 cc normal saline over 10 minutes before the above procedures, and 1 microgram per kilgram of body weight dexmedetomidine (Hospira, USA) added to the total volume of lid

DEX IV group: intravenous infusion of 1 microgram per kilogram of body weight dexmedetomidine (Hospira, USA) in a 20 cc syringe over 10 minutes before blocks, airway nerve blocks by lidocaine (5 mil

Eligibility

Sex/Gender

All

Age

18 Years to 66 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 18-66 year old; ASA class 1 or 2; elective surgery; probable difficult airway; probable injury to cervical spine Exclusion criteria: ASA >3; history of any cardiac disease; history of hypertension; history of renal function impairment; history of liver function impairment; history of opiod/recreational drug abuse; using anti hypertension drugs; usig alpha adrenergic agonists or antagonists; history of any psychological disorders; pregnancy; NPO time less than 8 hours for solid food and less than 3 hours for clear fluids; baseline heart rate less than 60 beats per minute; emergent/urgent surgeries; overt coagulopathy or impaired coagulation tests; history of diabetes mellitus

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Propofol consumption (milligrams per kilogram of body weight). Timepoint: at the time of reaching CSI score=75. Method of measurement: observation.	—

Secondary

Measure	Time frame
Intubation scores. Timepoint: at the time of bronchoscopy and intubation. Method of measurement: observation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactParisa Sezari MD

Shahid Beheshti University of MedicalSciences

psezari@sbmu.ac.ir; parissasezari@yahoo.com+98 912 219 4036

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026